Incrementally Modified Drug (IMD)

Incrementally Modified Drug (IMD)

http://korean-products.com/inquiry

Cilostan CR Tab

This product has improved the medication adaptation of patients by enabling them to take one tablet once a day through application of the Double- Controlled Release System which is a patented medication technology. In addition, this product is an antiplatelet agent of cilostazol that has minimized the side-effect of headache due to constant drug elution and it has an excellent effect on peripheral vascular diseases through vasodilation as well as antiplatelet function.

 

Clanza CR Tab

This product is an Aceclofenac-200mg NSAID, which can be taken once a day by applying the Double-Controlled Release System. The dual layer structure of 110mg of quick-release layer and 90mg of sustained- release layer has made the medicine work more quickly and allow the remedial effect to be sustained for up to 24 hours, so that patients suffering from chronic musculoskeletal pain can take the medicine for a long time without gastrointestinal side effects.

 

Gastiin CR tab

This is a mosapride product which is the most excellent drug among the prokinetics. This product is a functional indigestion improver that has made it possible to have a quick effect and keep the remedial effect for 24 hours and has improved the medication adaptation by taking one tablet once a day by separating the quick-release layer and the sustained-release layer through the Bilayered Drug Absorption System.

 

Homtamin

This product is a multivitamin supplement that contains the ginseng extract, and it is the top product in the sector of health tonics in Vietnam.
Korea United Pharma Inc. is a pharmaceutical company established in 1987, focusing on producing specialized medical substances. Since the inception of the company, it has focused on developing overseas markets and has established local factories in Vietnam, Egypt, and the United States. It has also established subsidiaries in major locations, such as Vietnam, the Philippines, Myanmar, Indonesia and Thailand, realizing its dream of becoming a multinational pharmaceutical company operated by Koreans. Based on active R&D investment of more than 13% of sales, it is becoming the top research-oriented pharmaceutical company in Korea, and is focusing on the development of IMD (Incrementally Modified Drug).
In particular, the improved new drug CILOSTAN CR achieved remarkable annual sales of KRW20 billion in 2016 as a single product. Thanks to these brilliant achievements and efforts, Korea United Pharm was selected as an innovative pharmaceutical company in 2012 and a World Class 300 project in 2014. In 2016, the improved new drugs CILOSTAN CR and CRANZA CR were selected as next- generation world-class products by Korea’s Ministry of Trade, Industry and Energy. Accordingly, the company’s technology and product excellence are increasingly recognized both inside and outside the country.

Korean-Products.com | Blog Magazine of Korean products, brands and Goods

Leave a Reply